NASDAQ:MXCT MaxCyte (MXCT) Stock Price, News & Analysis $2.25 -0.02 (-0.88%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$2.26 +0.00 (+0.22%) As of 07/25/2025 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About MaxCyte Stock (NASDAQ:MXCT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get MaxCyte alerts:Sign Up Key Stats Today's Range$2.18▼$2.2750-Day Range$2.02▼$2.3952-Week Range$2.00▼$5.20Volume334,871 shsAverage Volume487,858 shsMarket Capitalization$239.45 millionP/E RatioN/ADividend YieldN/APrice Target$7.00Consensus RatingBuy Company Overview MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland. Read More MaxCyte Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks64th Percentile Overall ScoreMXCT MarketRank™: MaxCyte scored higher than 64% of companies evaluated by MarketBeat, and ranked 379th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingMaxCyte has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMaxCyte has only been the subject of 1 research reports in the past 90 days.Read more about MaxCyte's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for MaxCyte are expected to grow in the coming year, from ($0.42) to ($0.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MaxCyte is -5.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MaxCyte is -5.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMaxCyte has a P/B Ratio of 1.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about MaxCyte's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.52% of the float of MaxCyte has been sold short.Short Interest Ratio / Days to CoverMaxCyte has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MaxCyte has recently decreased by 3.37%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMaxCyte does not currently pay a dividend.Dividend GrowthMaxCyte does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.52% of the float of MaxCyte has been sold short.Short Interest Ratio / Days to CoverMaxCyte has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MaxCyte has recently decreased by 3.37%, indicating that investor sentiment is improving. News and Social Media3.3 / 5News Sentiment0.87 News SentimentMaxCyte has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.07 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for MaxCyte this week, compared to 2 articles on an average week.Search Interest2 people have searched for MXCT on MarketBeat in the last 30 days. MarketBeat Follows1 people have added MaxCyte to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, MaxCyte insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.30% of the stock of MaxCyte is held by insiders.Percentage Held by Institutions68.81% of the stock of MaxCyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about MaxCyte's insider trading history. Receive MXCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MaxCyte and its competitors with MarketBeat's FREE daily newsletter. Email Address MXCT Stock News HeadlinesMaxCyte (NASDAQ:MXCT) Now Covered by StephensJuly 24 at 4:43 AM | americanbankingnews.comMaxCyte to Report Second Quarter 2025 Financial Results ... - MorningstarJuly 11, 2025 | morningstar.comM[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time could validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains. | Golden Portfolio (Ad)MaxCyte, Inc. to Release Second Quarter 2025 Financial Results on August 6th - NasdaqJuly 10, 2025 | nasdaq.comMaxCyte, Inc. to Release Second Quarter 2025 Financial Results on August 6thJuly 9, 2025 | quiverquant.comQMaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025July 9, 2025 | globenewswire.comPHC Announces Exclusive Distribution of MaxCyte® ExPERT™ Platform in JapanJuly 1, 2025 | businesswire.comMaxCyte and Ori Biotech Forge Strategic Partnership to Enhance Cell Therapy Manufacturing EfficiencyJune 12, 2025 | nasdaq.comSee More Headlines MXCT Stock Analysis - Frequently Asked Questions How have MXCT shares performed this year? MaxCyte's stock was trading at $4.16 at the beginning of 2025. Since then, MXCT shares have decreased by 45.9% and is now trading at $2.25. How were MaxCyte's earnings last quarter? MaxCyte, Inc. (NASDAQ:MXCT) released its quarterly earnings results on Wednesday, May, 7th. The company reported ($0.10) earnings per share for the quarter, hitting the consensus estimate of ($0.10). The company earned $10.39 million during the quarter, compared to analysts' expectations of $9.05 million. MaxCyte had a negative net margin of 110.92% and a negative trailing twelve-month return on equity of 19.90%. Read the conference call transcript. When did MaxCyte IPO? MaxCyte (MXCT) raised $150 million in an initial public offering (IPO) on Friday, July 30th 2021. The company issued 12,000,000 shares at a price of $11.50-$13.50 per share. Who are MaxCyte's major shareholders? Top institutional investors of MaxCyte include CWM LLC (0.01%) and Farther Finance Advisors LLC (0.01%). Insiders that own company stock include Casdin Partners Master Fund, L, Douglas Doerfler, Stanley C Erck, John Joseph Johnston, Douglas J Swirsky, Richard Douglas, Maher Masoud, David I Sandoval, Ali Soleymannezhad and Thomas M Ross. View institutional ownership trends. How do I buy shares of MaxCyte? Shares of MXCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of MaxCyte own? Based on aggregate information from My MarketBeat watchlists, some other companies that MaxCyte investors own include Tesla (TSLA), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), Netflix (NFLX) and Home Depot (HD). Company Calendar Last Earnings5/07/2025Today7/26/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBusiness Services Current SymbolNASDAQ:MXCT CIK1287098 Webmaxcyte.com Phone301-944-1700Fax301-944-1703Employees80Year FoundedN/APrice Target and Rating Average Price Target for MaxCyte$7.00 High Price Target$9.00 Low Price Target$6.00 Potential Upside/Downside+211.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$41.06 million Net Margins-110.92% Pretax Margin-110.92% Return on Equity-19.90% Return on Assets-17.24% Debt Debt-to-Equity RatioN/A Current Ratio12.23 Quick Ratio11.58 Sales & Book Value Annual Sales$38.63 million Price / Sales6.20 Cash FlowN/A Price / Cash FlowN/A Book Value$1.95 per share Price / Book1.15Miscellaneous Outstanding Shares106,420,000Free Float102,904,000Market Cap$239.45 million OptionableOptionable Beta1.23 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:MXCT) was last updated on 7/27/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MaxCyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MaxCyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.